Drugs / MK-5160
last change Jan 2018 re-read 2 minutes ago

MK-5160

Developed for
type 1 diabetes mellitus · type 2 diabetes mellitus
Investigated by
Merck Sharp & Dohme LLC

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03095651 Apr 2017 → Jan 2018 type 1 diabetes mellitus, type 2 diabetes mellitus Merck Sharp & Dohme LLC Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MK-5160 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03095651
Route Subcutaneous subcutaneous injection administered daily” NCT03095651